Modified FGF-21 Polypeptides and Their Uses
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 7 of these applications claim priority to application 60/921,297, filed Mar 30, 2007. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,012,931 | Modified FGF-21 Polypeptides and Their Uses In force · High confidence | Ambrx, Inc. | In force | High confidence | ||
| US 8,383,365 | Methods of Making FGF-21 Mutants Comprising Non-Naturally Encoded Phenylalanine Derivatives In force · High confidence | Ambrx, Inc. | In force | High confidence | ||
| US 9,079,971 | Modified FGF-21 Polypeptides comprising non-naturally occurring amino acids. In force · High confidence | Ambrx, Inc. | In force | High confidence | ||
| US 9,517,273 | Methods of Treatment Using Modified FGF-21 Polypeptides Comprising Non-Naturally Occurring Amino Acids In force · High confidence | Ambrx, Inc. | In force | High confidence | ||
| US 10,377,805 | Modified FGF-21 Polypeptides Comprising Non-Naturally Encoding Amino Acids and Their Uses In force · High confidence | Ambrx, Inc. | In force | High confidence | ||
| US 10,961,291 | Modified FGF-21 Polypeptides and Their Uses In force · High confidence | Ambrx, Inc. | In force | High confidence | ||
| US 11,993,637 | Modified FGF-21 Polypeptides with Non-Naturally Encoded Amino Acids In force · High confidence | Ambrx, Inc. | In force | High confidence | ||
| US 9,975,936 | Nucleic Acids Encoding Modified FGF-21 Polypeptides Comprising Non-Naturally Occurring Amino Acids Lapsed May 22, 2026 on the fee record Ended May 22, 2026 · High confidence | Ambrx, Inc. | Lapsed May 22, 2026 on the fee record | Ended May 22, 2026 | High confidence |
8 of 8 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
7 of these are in force and held by Ambrx, Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.